The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
 
David Planchard
No Relationships to Disclose
 
Harry J.M. Groen
Consulting or Advisory Role - GlaxoSmithKline (Inst); Lilly (Inst); Roche Pharma AG (Inst)
Research Funding - Lilly (Inst); Roche Pharma AG (Inst)
 
Tae Min Kim
No Relationships to Disclose
 
James R. Rigas
No Relationships to Disclose
 
Pierre Jean Souquet
Honoraria - AstraZeneca; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Lilly/ImClone; PFIZER; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; boehringer ingelheim; Lilly/ImClone; pfizer; Roche/Genentech
Research Funding - AstraZeneca; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; LILLY (Inst); Novartis; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - LILLY; PFIZER
 
Christina S. Baik
Honoraria - Novartis
Research Funding - Clovis Oncology (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Millennium (Inst); Novartis (Inst)
 
Fabrice Barlesi
Honoraria - AstraZeneca; Genentech/Roche; GlaxoSmithKline; Lilly; Novartis; Pfizer; Pierre Fabre
Consulting or Advisory Role - Genentech/Roche
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly/ImClone (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Lilly; Novartis; Novartis
 
Julien Mazières
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly/ImClone; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech
Research Funding - Puma Biotechnology; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Elisabeth A. Quoix
Consulting or Advisory Role - Roche/Genentech
Travel, Accommodations, Expenses - Roche
 
C. Martin Curtis
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Bijoyesh Mookerjee
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Incyte
 
Arundathy N. Bartlett-Pandite
Employment - GlaxoSmithKline
Leadership - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
 
Christine Tucker
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Anthony D'Amelio
Employment - GlaxoSmithKline
Stock and Other Ownership Interests - GlaxoSmithKline
 
Bruce E. Johnson
Stock and Other Ownership Interests - KEW
Honoraria - Chugai Pharma; Merck
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Dana-Farber Cancer Institute; GE Healthcare; KEW; Merck; Novartis; Otsuka; Puma Biotechnology; Synta; Teva; Transgene
Patents, Royalties, Other Intellectual Property - Dana-Farber Cancer Institute
Expert Testimony - Genentech